Jack­ie Fouse gets back in­to bio­phar­ma as ex­ec­u­tive chair­man of Der­ma­vant; Ex-GSK chief An­drew Wit­ty joins a biotech board

→ A lit­tle more than four months af­ter Jack­ie Fouse said she was “re­tir­ing” as pres­i­dent of Cel­gene, she’s back run­ning her own biotech as ex­ec­u­tive chair­man of Der­ma­vant, one of sev­er­al new “vants” that Roivant chief Vivek Ra­maswamy has kicked in­to play over the last three years.

Tony Wood, Pfiz­er’s se­nior vice pres­i­dent of med­i­c­i­nal sci­ences, has been wooed over to take a key R&D post­ing at the UK phar­ma gi­ant. And the move in­cludes a shift in as­sign­ments tied to a new ef­fort at GSK in­volv­ing the use of ar­ti­fi­cial in­tel­li­gence in drug de­vel­op­ment. John Bal­doni, who pre­vi­ous­ly led this ef­fort, is mov­ing to head up a new team fo­cused on “en­hanc­ing drug dis­cov­ery through the use of in sil­i­co tech­nol­o­gy — in­clud­ing ar­ti­fi­cial in­tel­li­gence, ma­chine learn­ing and deep learn­ing.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.